GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies, a spin-off from General Electric, is performing well with a market cap of around $35 billion and strong tailwinds in the healthcare industry. The company operates in four business segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The company's Q1 performance showed impressive revenue growth, improved margins, and a robust backlog, indicating future growth potential.

GE HealthCare: A Good Future Dividend Growth Stock?

CHICAGO--(BUSINESS WIRE)--At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting, GE HealthCare (Nasdaq: GEHC) is proud to showcase new, innovative technologies and diagnostics that enable personalized medicine and precision care to help clinicians improve patient outcomes around the world. This includes the introduction of new artificial intelligence (AI) solutions for enhanced image quality; the advancement of Theranostics; and achievement of new milestones in th.

From General to Personalized Care: GE HealthCare is Focused on Disease Detection and More Holistic and Effective Treatment Options

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC), a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today declared a cash dividend of $0.03 per share of Common Stock for the second quarter of 2023 payable on August 15, 2023 to all shareholders of record as of July 21, 2023. About GE HealthCare GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator.

GE HealthCare Announces Cash Dividend for Second Quarter of Fiscal Year 2023

CHICAGO--(BUSINESS WIRE)--GE HealthCare is set to unveil SIGNA PET/MR AIRi, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting. The company will showcase the integration of its advanced AIR technologies with the SIGNA PET/MR AIR system, to enhance diagnostic precision, simplify treatment evaluation, while elevating patient comfort. Recent FDA approvals of new PET radiotracers and therapeutic approaches for high-prevalence diseases, such as prostate cancer and A.

GE HealthCare Advances PET/MR Capabilities with AIR Technologies

CHICAGO--(BUSINESS WIRE)--GE HealthCare has entered into a distribution agreement with DePuy Synthes to bring OEC 3D Imaging System to more surgeons and patients in U.S.

GE HealthCare Announces Collaboration with DePuy Synthes to Bring Advanced 3D Precision Imaging Innovation to Spine Practices in the United States

GE Healthcare is a leading global medical technology and digital solutions company with significant growth potential, driven by macro trends such as precision health, digitization, and improved access to healthcare. The company's financial performance, management incentives, and competitive landscape support its growth trajectory, with an estimated valuation indicating a potential stock price increase of at least 66% within 18 to 24 months. Risks include regulatory and compliance challenges, competitive pressures, and the need to stay at the forefront of technological disruptions in the healthcare industry.

GE HealthCare: Leading The Way In Transforming Healthcare

The spinoff from GE was likely met with some hesitancy from institutional buyers. GE HealthCare's valuation remains compelling despite its substantial rise this year.

Why It's a Great Time to Buy GE HealthCare Stock

GE Healthcare shares are sliding Thursday, creating a chance to buy this medical-technology company at an increasingly attractive valuation.

Cramer says snap up this leading medtech stock — wishes he could buy shares too

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $78.00 per share. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exc.

GE HealthCare Technologies Inc. Prices Secondary Offering of 25,000,000 Shares

A new survey from GE Healthcare reveals that clinicians lack trust in AI when it comes to using the technology in medical settings.

Lack of trust slowing down AI revolution in medical settings: GE Healthcare report

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today released Reimagining Better Health, a qualitative and quantitative study that amplifies the perspectives and needs of people at the center of healthcare —patients and clinicians. The study aims to help inform a path forward as stressors such as burnout, workforce attrition and patient backlogs test the resiliency of health systems. Participants.

GE HealthCare Reimagining Better Health Study Identifies the Barriers to Achieving a More Human and Flexible Healthcare Experience

GE HealthCare Technologies GEHC, +0.65% stock was down 3% premarket on Tuesday after the company announced late Monday that General Electric Co. GE, -1.58% plans to sell 25 million shares, or about $2 billion, of the medical technology company in a debt-for-equity exchange. In connection with the offering, GE is expected to exchange up to 28.75 million shares of GE HealthCare Technologies for GE debt held by affiliates of Morgan Stanley, according to a regulatory filing.

GE HealthCare Technologies shares slide as GE plans share offering

General Electric

General Electric Co is offering 25 million of common stock, or over a $2 billion stake, in GE HealthCare Technologies Inc , according to a regulatory filing on Monday.

General Electric to sell over $2 bln stake in GE HealthCare

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 25,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, Gener.

GE HealthCare Technologies Inc. Commences Secondary Offering of 25,000,000 Shares

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based technology designed to dramatically accelerate image acquisition in magnetic resonance imaging (MRI). Sonic DL enables new imaging paradigms, such as high-quality cardiac MRI in a single heartbeat. This breakthrough expands GE HealthCare's industry-leading AI-enabled solutions portfolio. Cardiac MRI is the gold standard for assessing the struct.

GE HealthCare Introduces Sonic DL: A Groundbreaking, FDA-Cleared AI Deep Learning Technology for Faster MRI

Lantheus Holdings

After soaring this year, shares of Nano-X are looking a bit rich. Lantheus has a product that helps detect the presence of prostate cancer.

2 Medical Imaging Stocks That Are Better Buys Than Nano-X

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced US FDA 510(k) clearance of Precision DL – a new, revolutionary deep learning-based image processing software included in GE HealthCare's growing Effortless Recon DL portfolio. Precision DL provides the image quality performance benefits typically associated with hardware-based Time-of-Flight (ToF) reconstruction, including improved contrast-to-noise ratioi, contrast recoveryi, and quantitative accuracyii. The AI-based techno.

GE HealthCare Receives FDA Clearance of a New Deep Learning Solution for Enhanced Image Quality in PET/CT, Advancing its Leadership Position in AI

Inmode Ltd

Intuitive Surgical

Johnson & Johnson

CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.

Solid Earnings Fuel Potential Bull Market in Medical Devices

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading medical technology innovator, announced today its largest ever CT deal in the United States – a $30 million order by St. Luke's University Health Network, a nationally recognized nonprofit healthcare network, to install 21 of GE HealthCare's innovative CT systems, powered by Artificial Intelligence (AI), across their system. This order builds upon the more than 30-year relationship between the two organizations. The new scanners.

St. Luke's University Health Network Selects GE HealthCare for $30 Million Purchase of Cutting-Edge CT Technology, Powered by Artificial Intelligence

NEW YORK--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, is announcing today that its President and CEO Peter Arduini will present at the Jefferies Healthcare Conference in New York City on June 7, 2023 from 10:30 am to 10:55 am ET. This event can be accessed live by visiting GE HealthCare's Investor Relations website at: https://wsw.com/webcast/jeff281/gehc/1817530. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology.

GE HealthCare to Present at Jefferies Healthcare Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)--GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

VIENNA--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is presenting three new global innovations – Intelligent Radiation Therapy (iRT), Auto Segmentation, and an updated Magnetic Resonance (MR) Radiation Therapy Suite (AIR Open Coil Suite) – that underscore the company's commitment to enhancing the radiation oncology care pathway. Each of these novel solutions, which will be showcased at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2023 Congress, were designed to help emp.

GE HealthCare Introduces Innovations to Improve Radiation Therapy Efficiency and Precision Care at the European Society for Therapeutic Radiology and Oncology 2023 Congress

CHICAGO--(BUSINESS WIRE)--GE HealthCare has named James "Jay” Saccaro as vice president and chief financial officer (CFO), succeeding Helmut Zodl, who will remain at GEHC.

GE HealthCare Names James Saccaro Vice President and Chief Financial Officer

DexCom

Medtronic

Increasingly, technologies other than drugs are working to improve patient health. From diagnostic systems like MRIs and CAT scans to high-tech glucose monitoring systems to devices that destroy tumors, medicine makes use of many such technologies.

3 HealthTech Stocks to Watch as Digital Health Transforms the Industry

GEHC, $81.52, Market Capitalization $37.1 billion), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, reported 1Q23 results with a beat on both revenue and EPS versus consensus.

News for GE HealthCare Technologies Inc Stock (GEHC)